Abstract
Hypoglycemia is common in insulin, sulfonylurea, or glinide-treated diabetes where it is typically the result of the interplay of therapeutic insulin excess and compromised physiological and behavioral defenses against falling glucose levels. It is uncommon in the absence of diabetes where it is most commonly caused by drugs including alcohol among many others. Hypoglycemia is suggested by neurogenic (autonomic) and neuroglycopenic symptoms and signs of sympathoadrenal activation. It is confirmed by documentation of a low plasma glucose concentration with resolution of symptoms and signs after the glucose level is raised. In the short-term it is treated with oral carbohydrate, subcutaneous glucagon, or intravenous glucose. In the long term it is prevented by correction of its original cause.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cryer PE. Hypoglycemia in diabetes. Pathophysiology, prevalence and prevention. 2nd ed. Alexandria, VA: American Diabetes Association; 2012.
Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, et al. Evaluation and management of adult hypoglycemic disorders: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94:709–28.
Murad MH, Coto-Yglesias F, Wang AT, Sheidaee N, Mullan RJ, Elamin MB, et al. Clinical review: Drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab. 2009;94:741–5.
Ben Salem C, Fathallah N, Hmouda H, Bouraoui K. Drug-induced hypoglycaemia: An update. Drug Saf. 2011;34:21–45.
Wiethop BV, Cryer PE. Alanine and terbutaline in treatment of hypoglycemia in IDDM. Diabetes Care. 1993;16:1131–6.
Gunning RR, Garber AJ. Bioactivity of instant glucose. Failure of absorption through oral mucosa. JAMA. 1978;240:1611–2.
Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care. 2001;24:643–5.
Basu R, Basu A, Johnson CM, Schwenk WF, Rizza RA. Insulin dose–response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in nondiabetic humans and are abnormal in people with type 2 diabetes. Diabetes. 2004;53:2042–50.
Boyle PJ, Justice K, Krentz AJ, Nagy RJ, Schade DS. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab. 1993;76:752–6.
Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with diabetes onset before the age of 31. I. Survival, causes of death, and complications. Diabetologia. 1978;14:363–70.
Tunbridge WMG. Factors contributing to deaths of diabetics under 50 years of age. Lancet. 1981;2:569–72.
Laing SP, Swerdlow AJ, Slater SD, Botha JL, Burden AC, Waugh NR, et al. The British Diabetic Association Cohort Study. I: All-cause mortality in patients with insulin-treated diabetes mellitus. Diabet Med. 1999;16:459–65.
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, Jacobson AM, Musen G, Ryan CM, Silvers N, Cleary P, Waberski B, Burwood A, Weinger K, Bayless M, Dahms W, Harth J. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 356:1842–1852, 2007.
Feltbower RG, Bodansky HJ, Patterson CC, Parslow RC, Stephenson CR, Reynolds C, et al. Acute complications and drug misuse are important causes of death for children and young adults with type 1 diabetes: results from the Yorkshire Register of diabetes in children and young adults. Diabetes Care. 2008;31:922–6.
Skrivarhaug T, Bangstad H-J, Stene LC, Sandvik L, Hanssen KF, Joner G. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia. 2006;49:298–305.
Gerich JE. Oral hypoglycemic agents. N Engl J Med. 1989;321:1231–45.
Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes. 2003;111:405–14.
Control D, Group CTR. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.
Prospective UK. Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
Prospective UK. Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65.
Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.
Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med. 2005;22:749–55.
Hypoglycaemia Study Group UK. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140–7.
Cryer PE. The prevention and correction of hypoglycemia. In: Jefferson LS, Cherrington AD, editors. Handbook of physiology, Section 7, The endocrine pancreas and regulation of metabolism, vol. II. New York: Oxford University Press; 2001. p. 1057–92.
Cooperberg BA, Cryer PE. Insulin reciprocally regulates glucagon secretion in humans. Diabetes. 2010;59:2936–40.
White NH, Skor DA, Cryer PE, Levandoski LA, Bier DM, Santiago JV. Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med. 1983;308:485–91.
Bolli GB, De Feo P, De Cosmo S, Perriello G, Ventura MM, Benedetti MM, et al. A reliable and reproducible test for adequate glucose counterregulation in type I diabetes mellitus. Diabetes. 1984;33:732–7.
Towler DA, Havlin CE, Craft S, Cryer P. Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes. 1993;42:1791–8.
DeRosa MA, Cryer PE. Hypoglycemia and the sympathoadrenal system: neurogenic symptoms are largely the result of sympathetic neural, rather than adrenomedullary, activation. Am J Physiol Endocrinol Metab. 2004;287:E32–41.
Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Diabet Med. 2008;25:501–4.
Schopman JE, Geddes J, Frier BM. Prevalence of impaired awareness of hypoglycaemia and frequency of hypoglycaemia in insulin-treated type 2 diabetes. Diabetes Res Clin Pract. 2010;87:64–8.
Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. J Clin Invest. 1993;91:819–28.
Fanelli CG, Epifano L, Rambotti AM, Pampanelli S, Di Vincenzo A, Modarelli F, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes. 1993;42:1683–9.
Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet. 1994;344:283–7.
Fanelli C, Pampanelli S, Epifano L, Rambotti AM, Di Vincenzo A, Modarelli F, et al. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia. 1994;37:1265–76.
Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes. 1994;43:1426–34.
Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes. 2002;51:724–33.
Cryer PE. Hypoglycemia. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, editors Williams textbook of endocrinology. 12th ed. Saunders, Philadelphia. 2011;1552–77.
Control D, Complications Trial Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med. 1991;90:450–9.
Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26:1902–12.
Acknowledgments
The author’s original work cited was supported, in part, by National Institutes of Health grants R37 DK27085, MO1 RR00036 (now UL1 RR24992), P60 DK20579, and T32 DK07120 and by a fellowship award from the American Diabetes Association. Ms. Janet Dedeke, the author’s assistant, prepared this manuscript.
The author has served as a consultant to Novo Nordisk in the past year. He does not receive research funds from, hold stock in, or speak for any pharmaceutical or device firm.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Cryer, P.E. (2014). Hypoglycemia. In: Loriaux, L. (eds) Endocrine Emergencies. Contemporary Endocrinology, vol 74. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-697-9_3
Download citation
DOI: https://doi.org/10.1007/978-1-62703-697-9_3
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-696-2
Online ISBN: 978-1-62703-697-9
eBook Packages: MedicineMedicine (R0)